NCT00535418
Completed
Phase 2
Pre-operative Hormone Therapy for Postmenopausal Women With ER and/or PgR Positive Breast Cancer: An Uncontrolled Phase IIb/III Trial to Assess Optimal Duration of Pre-operative Treatment With Letrozole and to Correlate Clinical Efficacy With Appropriate Surrogate Markers
Overview
- Phase
- Phase 2
- Intervention
- Letrozole
- Conditions
- Breast Cancer
- Sponsor
- Novartis Pharmaceuticals
- Enrollment
- 35
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
This study will assess optimal duration of pre-operative treatment with letrozole and to correlate clinical efficacy with appropriate surrogate markers.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Arms & Interventions
Letrozole
Intervention: Letrozole
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast CancerBreast Cancer FemaleNCT03747042University of Texas Southwestern Medical Center61
Completed
Phase 2
Neoadjuvant Endocrine Therapy in Breast CancerHighly Endocrine Responsive Operable Breast CancerNCT03397537Guangdong Provincial People's Hospital46
Active, not recruiting
Not Applicable
Preoperative hormone therapy for pre- and postmenopausal women with ER positive breast cancer: A double blind randomized parallel group phase II trial, comparing the effect of 2 weeks of preoperative Estetrol with placebo - Preoperative estetrolbreast cancerEUCTR2006-006542-34-ATPantarhei Bioscience B.V.
Terminated
Early Phase 1
Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by SurgeryBreast CancerNCT00651976Vanderbilt-Ingram Cancer Center213
Completed
Phase 2
Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast CancerPostmenopausal Women With Advanced Breast CancerNCT00237211Novartis Pharmaceuticals31